Clinical trial POLARIS-2
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia
| Organ | LMC |
|---|---|
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Ascentage Pharma Group Inc |
| EudraCT Identifier | 2024-511495-32-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06423911 |
| Last update |